Maximus Stock Forecast, Price & News

Maximus (NYSE:MMS) Frequently Asked Questions

Is Maximus a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maximus in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Maximus stock.
View analyst ratings for Maximus or view top-rated stocks.

What stocks does MarketBeat like better than Maximus?

Wall Street analysts have given Maximus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Maximus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Maximus' next earnings date?

Maximus is scheduled to release its next quarterly earnings announcement on Thursday, November 18th 2021.
View our earnings forecast for Maximus.

How were Maximus' earnings last quarter?

Maximus, Inc. (NYSE:MMS) released its earnings results on Thursday, August, 5th. The health services provider reported $1.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.09 by $0.42. The health services provider earned $1.24 billion during the quarter, compared to analyst estimates of $1.09 billion. Maximus had a trailing twelve-month return on equity of 23.25% and a net margin of 7.44%. Maximus's revenue for the quarter was up 38.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.04 earnings per share.
View Maximus' earnings history.

How has Maximus' stock been impacted by COVID-19?

Maximus' stock was trading at $60.94 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MMS stock has increased by 38.2% and is now trading at $84.21.
View which stocks have been most impacted by COVID-19.

How often does Maximus pay dividends? What is the dividend yield for Maximus?

Maximus declared a quarterly dividend on Thursday, October 14th. Investors of record on Monday, November 15th will be given a dividend of $0.28 per share on Tuesday, November 30th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.33%. The ex-dividend date is Friday, November 12th.
View Maximus' dividend history.

Is Maximus a good dividend stock?

Maximus pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.30%. The dividend payout ratio of Maximus is 33.04%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Maximus will have a dividend payout ratio of 25.06% next year. This indicates that Maximus will be able to sustain or increase its dividend.
View Maximus' dividend history.

What guidance has Maximus issued on next quarter's earnings?

Maximus issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of $4.650-$4.750 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.330. The company issued revenue guidance of $4.20 billion-$4.25 billion, compared to the consensus revenue estimate of $4.06 billion.

What price target have analysts set for MMS?

2 equities research analysts have issued 12-month price targets for Maximus' shares. Their forecasts range from $95.00 to $105.00. On average, they expect Maximus' stock price to reach $100.00 in the next twelve months. This suggests a possible upside of 18.8% from the stock's current price.
View analysts' price targets for Maximus or view top-rated stocks among Wall Street analysts.

Who are Maximus' key executives?

Maximus' management team includes the following people:

• Bruce L. Caswell, Co-President, Chief Executive Officer & Director
• Manish Agarwal, Co-President
• Richard J. Nadeau, Chief Financial Officer & Treasurer
• Michael S. Weiner, Chief Medical Officer
• John W. Lambeth, Chief Information Officer

What is Bruce Caswell's approval rating as Maximus' CEO?

145 employees have rated Maximus CEO Bruce Caswell on Glassdoor.com. Bruce Caswell has an approval rating of 80% among Maximus' employees.

Who are some of Maximus' key competitors?

Some companies that are related to Maximus include Visa (V), Mastercard (MA), Automatic Data Processing (ADP), Fidelity National Information Services (FIS), Fiserv (FISV), Global Payments (GPN), Paychex (PAYX), FLEETCOR Technologies (FLT), Broadridge Financial Solutions (BR), Jack Henry & Associates (JKHY), Genpact (G), WEX (WEX), The Western Union (WU), Euronet Worldwide (EEFT) and Alliance Data Systems (ADS).
View all of MMS's competitors.

What other stocks do shareholders of Maximus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Maximus investors own include Pfizer (PFE), Lennar (LEN), AbbVie (ABBV), Cisco Systems (CSCO), The Kroger (KR), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD), Cerner (CERN), Intel (INTC) and JD.com (JD).

What is Maximus' stock symbol?

Maximus trades on the New York Stock Exchange (NYSE) under the ticker symbol "MMS."

Who are Maximus' major shareholders?

Maximus' stock is owned by a number of retail and institutional investors. Top institutional investors include Copeland Capital Management LLC (0.80%), DekaBank Deutsche Girozentrale (0.55%), Reinhart Partners Inc. (0.48%), Robeco Schweiz AG (0.40%), Cambiar Investors LLC (0.17%) and Chatham Capital Group Inc. (0.05%). Company insiders that own Maximus stock include Bruce Caswell, David Francis, Michelle F Link, Peter Pond, Raymond B Ruddy, Richard A Montoni, Richard John Nadeau and Thomas D Romeo.
View institutional ownership trends for Maximus.

Which institutional investors are selling Maximus stock?

MMS stock was sold by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Reinhart Partners Inc., Strs Ohio, Cambiar Investors LLC, Chatham Capital Group Inc., Oregon Public Employees Retirement Fund, Louisiana State Employees Retirement System, and Pacer Advisors Inc.. Company insiders that have sold Maximus company stock in the last year include David Francis, Michelle F Link, Peter Pond, Raymond B Ruddy, Richard A Montoni, Richard John Nadeau, and Thomas D Romeo.
View insider buying and selling activity for Maximus or view top insider-selling stocks.

Which institutional investors are buying Maximus stock?

MMS stock was acquired by a variety of institutional investors in the last quarter, including Robeco Schweiz AG, DekaBank Deutsche Girozentrale, Copeland Capital Management LLC, Orrstown Financial Services Inc., Liberty Capital Management Inc., Crossmark Global Holdings Inc., Avantax Advisory Services Inc., and First Citizens Bank & Trust Co..
View insider buying and selling activity for Maximus or or view top insider-buying stocks.

How do I buy shares of Maximus?

Shares of MMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Maximus' stock price today?

One share of MMS stock can currently be purchased for approximately $84.21.

How much money does Maximus make?

Maximus has a market capitalization of $5.18 billion and generates $3.46 billion in revenue each year. The health services provider earns $214.51 million in net income (profit) each year or $3.39 on an earnings per share basis.

How many employees does Maximus have?

Maximus employs 34,300 workers across the globe.

When was Maximus founded?

Maximus was founded in 1975.

What is Maximus' official website?

The official website for Maximus is www.maximus.com.

Where are Maximus' headquarters?

Maximus is headquartered at 1891 METRO CENTER DRIVE, RESTON VA, 20190.

How can I contact Maximus?

Maximus' mailing address is 1891 METRO CENTER DRIVE, RESTON VA, 20190. The health services provider can be reached via phone at (703) 251-8500 or via email at [email protected].